Microtubule-associated protein tau oligomers (TauO)

Microtubule-associated protein tau oligomers (TauO) are soluble, intermediate aggregates of the tau protein that form during the progression of Alzheimer's disease and other tauopathies [1][4]. Unlike the insoluble neurofibrillary tangles (NFTs) which were historically considered the primary drivers of neurodegeneration, recent evidence suggests that these smaller, soluble oligomers are the most neurotoxic species [3][8]. They contribute to disease pathology by disrupting synaptic function, impairing mitochondrial activity, and promoting the 'prion-like' spreading of misfolded tau throughout the brain [10][13][19]. Therapeutic strategies targeting tau oligomers include monoclonal antibodies designed to clear these aggregates, small molecules that inhibit their formation, and vaccines that stimulate an immune response against pathological tau species [1][3][11]. A major challenge in targeting tau oligomers is their structural heterogeneity and the need to achieve high selectivity to avoid interfering with the physiological role of monomeric tau in stabilizing microtubules [4][8][17]. Current clinical efforts are focused on identifying specific toxic epitopes and developing biomarkers, such as CSF and plasma p-tau levels, to monitor treatment efficacy [12][20].

Other names

Tau oligomersSoluble tau aggregatesPathogenic tau oligomersTauOMisfolded tau oligomersTau toxic species

Inhibition of tau aggregation, clearance of soluble tau oligomers via immunotherapy, and prevention of tau seeding and propagation [1][3][8].